Helus Pharma reports positive Phase 3 results for deuterated psilocin as an adjunctive treatment for depression
Summary
Helus Pharma reported positive topline results for HLP003, a deuterated psilocin treatment tested alongside antidepressants in adults with major depressive disorder. In the randomized, double-blind, placebo-controlled Phase 3 trial of 222 participants, depression scores improved by 7.6 points more than placebo at six weeks and by 7.0 points more at 12 weeks. Improvements in response and remission rates were reported from Day 2. Most adverse events were mild to moderate and transient, but three serious adverse events were treatment-related. A second pivotal trial and a long-term extension study are ongoing; regulatory approval and commercialization remain uncertain.